2018’s Top Ten Drugs

Humira, AbbVie’s TNF inhibitor, will lead the pack again in 2018 with an expected $20 B in sales, the first drug to ever pass that threshold.  It will more than double the sales of Revlimid which holds the number two spot at $9.2 B in sales. Not surprisingly, five of the top ten spots belong to cancer treatments and the remaining are medications for diseases of the retina, auto immune disease and a blood clots.










For more information on how we can help you with your pharmacy solutions, please contact us today!

Source: 2018’s Best-Sellers? AbbVie’s Humira, Obviously, but Newcomers are on Their Way